Comparative study on the effectiveness of drugs for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by the elevation of the mean pulmonary arterial pressure (mPAP) that leads to morbidity and premature mortality. Although PAH affects males and females of all ethnicities and ages, the disease most commonly affects women and people between 20 and 40 years of age. In adults, the prevalence of PAH is approximately 12 to 50 cases per million people. PAH is classified as Group 1 of the pulmonary hypertension (PH) classification. Four subgroups of Group 1 include idiopathic PAH, heritable or familial PAH, drug- and toxin-induced PAH, and PAH associated with concurrent medical conditions such as connective tissue disease, HIV infection, portal hypertension, congenital heart disease, or schistosomiasis.